Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
Exploratory 3-year overall survival for patients with unresectable... | Download Scientific Diagram
AstraZeneca presents superior progression-free survival for IMFINZI® ( durvalumab) in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Decision making process diagram to evaluate candidate patients for... | Download Scientific Diagram
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
PACIFIC phase III trial scheme. | Download Scientific Diagram
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology
PACIFIC: Durvalumab in Stage III NSCLC - Capsule Summary Slidesets - 2018 WCLC Annual Meeting - Oncology - Clinical Care Options
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
First-line Durvalumab Improves Survival
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
david vicente baz on Twitter: "Very proud of our contribution to PACIFIC clinical trial. Durvalumab as new standard of care in unresectable stage III non small cell lung cancer after chemoradiotherapy Many
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
